

Catalent, Inc.  
Form 8-K  
December 02, 2016

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, DC 20549**

**FORM 8-K**

**CURRENT REPORT**  
**PURSUANT TO SECTION 13 OR 15(d)**  
**OF THE SECURITIES EXCHANGE ACT OF 1934**  
**Date of Report (Date of earliest event reported): December 2, 2016**

**CATALENT, INC.**

**(Exact name of registrant as specified in its charter)**

**Delaware**  
**(State or other jurisdiction**

**of Incorporation)**

**14 Schoolhouse Road**

**001-36587**  
**(Commission**

**File Number)**

**20-8737688**  
**(IRS Employer**

**Identification Number)**

**08873**

**Somerset, New Jersey**  
**(Address of registrant's principal executive office)**  
**(732) 537-6200**

**(Zip code)**

**(Registrant's telephone number, including area code)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 203.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01 Other Items.**

On December 2, 2016, Catalent, Inc. (the Company ) issued a press release announcing that its wholly owned subsidiary, Catalent Pharma Solutions, Inc. (the Operating Company ), has priced a private offering (the Private Offering ) of 380.0 million aggregate principal amount (\$404.5 million U.S. dollar equivalent) of 4.75% senior unsecured notes due 2024 (the Notes ) at par. The full text of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

**Exhibit**

<b>No.</b>	<b>Description</b>
99.1	Press Release of Catalent, Inc., dated December 2, 2016, announcing pricing of notes offering.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Catalent, Inc.  
(Registrant)

By: /s/ Steven L. Fasman  
Steven L. Fasman  
Senior Vice President & General Counsel

and Secretary

Date: December 2, 2016

EXHIBIT LIST

**Exhibit**

<b>No.</b>	<b>Description</b>
99.1	Press Release of Catalent, Inc., dated December 2, 2016, announcing pricing of notes offering.